

Melenda Jeter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3732456/publications.pdf>

Version: 2024-02-01

24
papers

769
citations

759233

12
h-index

752698

20
g-index

24
all docs

24
docs citations

24
times ranked

1081
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Fraction Stereotactic vs Conventional Multifraction Radiotherapy for Pain Relief in Patients With Predominantly Nonspine Bone Metastases. <i>JAMA Oncology</i> , 2019, 5, 872.	7.1	146
2	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, e172032.	7.1	119
3	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 667-676.	0.8	79
4	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 266-273.	1.1	58
5	Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 558-563.	0.8	55
6	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1919-1927.	1.1	53
7	Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 983-992.	1.1	51
8	Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. <i>JAMA Network Open</i> , 2018, 1, e181390.	5.9	48
9	Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 274-280.	0.6	38
10	Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 900-907.	0.8	37
11	Clinical outcomes after intensity-modulated proton therapy with concurrent chemotherapy for inoperable non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2019, 136, 136-142.	0.6	21
12	High-Flow Nasal Cannula Therapy for Exertional Dyspnea in Patients with Cancer: A Pilot Randomized Clinical Trial. <i>Oncologist</i> , 2021, 26, e1470-e1479.	3.7	15
13	Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. <i>Quality of Life Research</i> , 2018, 27, 1563-1570.	3.1	12
14	Polymorphisms in BMP2/BMP4, with estimates of mean lung dose, predict radiation pneumonitis among patients receiving definitive radiotherapy for non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 43080-43090.	1.8	9
15	I-SABR phase II randomized study of nivolumab immunotherapy and stereotactic ablative radiotherapy in early stage NSCLC: Interim analysis adverse effects.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9035-9035.	1.6	8
16	The Pulmonary Fibrosis Associated MUC5B Promoter Polymorphism Is Prognostic of the Overall Survival in Patients with Non-Small Cell Lung Cancer (NSCLC) Receiving Definitive Radiotherapy. <i>Translational Oncology</i> , 2017, 10, 197-202.	3.7	7
17	Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 54-61.	1.7	5
18	Nomograms incorporating genetic variants in BMP/Smad4/Hamp pathway to predict disease outcomes after definitive radiotherapy for non-small cell lung cancer. <i>Cancer Medicine</i> , 2018, 7, 2247-2255.	2.8	4

#	ARTICLE	IF	CITATIONS
19	Salvage guideline for local-regional failure after stereotactic ablative radiotherapy for early-stage non-small cell lung cancer.. Journal of Clinical Oncology, 2017, 35, 8501-8501.	1.6	3
20	Time driven activity-based costing methods used in radiation oncology clinics.. Journal of Clinical Oncology, 2019, 37, 79-79.	1.6	1
21	Normal-lung uptake of fluorodeoxyglucose, patient-reported symptoms, and clinician-rated radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation.. Journal of Clinical Oncology, 2016, 34, e20028-e20028.	1.6	0
22	Measuring cost in the value equation using time-driven activity-based costing (TDABC) at The University of Texas MD Anderson Cancer Center, Division of Radiation Oncology.. Journal of Clinical Oncology, 2017, 35, e18305-e18305.	1.6	0
23	Effect of high flow oxygen on exertional dyspnea in cancer patients: A double-blind randomized clinical trial.. Journal of Clinical Oncology, 2019, 37, 11600-11600.	1.6	0
24	Single-fraction stereotactic versus standard conventional multifraction radiation for predominantly non-spine bone metastases: A randomized phase II trial.. Journal of Clinical Oncology, 2019, 37, 11578-11578.	1.6	0